Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IACS-56676
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
01
Overview
IACS-56676: sourced facts only. name: "Herein, we describe the structure-guided development of IACS-56676, a selective and potent NRAS G12D inhibitor useful as a tool compound for further studies of NRAS biology." [PMID:41704364]; target: "Herein, we describe the structure-guided development of IACS-56676, a selective and potent NRAS G12D inhibitor useful as a tool compound for further studies of NRAS biology." [PMID:41704364]; developer: "Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, Texas 77054, United States." [PMID:41704364]
02
Targets
NRAS (Neuroblastoma RAS viral oncogene homolog)
Beyond the preview
Go deeper on IACS-56676.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IACS-56676.